coin-img-ETHETH-1.28%coin-img-ZECZEC-1.05%coin-img-SOLSOL-2.83%coin-img-BTCBTC-1.55%coin-img-XRPXRP-3.21%coin-img-USDCUSDC+0.02%coin-img-DOGEDOGE-6.12%coin-img-HYPEHYPE-3.59%coin-img-ETHETH-1.28%coin-img-ZECZEC-1.05%coin-img-SOLSOL-2.83%coin-img-BTCBTC-1.55%coin-img-XRPXRP-3.21%coin-img-USDCUSDC+0.02%coin-img-DOGEDOGE-6.12%coin-img-HYPEHYPE-3.59%coin-img-ETHETH-1.28%coin-img-ZECZEC-1.05%coin-img-SOLSOL-2.83%coin-img-BTCBTC-1.55%coin-img-XRPXRP-3.21%coin-img-USDCUSDC+0.02%coin-img-DOGEDOGE-6.12%coin-img-HYPEHYPE-3.59%coin-img-ETHETH-1.28%coin-img-ZECZEC-1.05%coin-img-SOLSOL-2.83%coin-img-BTCBTC-1.55%coin-img-XRPXRP-3.21%coin-img-USDCUSDC+0.02%coin-img-DOGEDOGE-6.12%coin-img-HYPEHYPE-3.59%
user-avatar
Arnne Carragie

AbbVie (ABBV) Q2 2026 Earnings Overview: EPS Rises 22.9% as Immunology Drug Growth Fails to Prevent 2.51% Selloff

AI Market Summary
AbbVie's Q2 2026 results beat consensus on revenue ($16.99B, +10.2%) and adjusted EPS ($3.65), driven by strong Skyrizi/Rinvoq (+24%+, $8.03B combined) and neuroscience growth, offsetting continued Humira erosion (-35.9%). Despite a raised revenue outlook, management trimmed full-year adjusted EPS guidance due to expected Apogee deal dilution, reinforcing a high-expectations setup and pressuring shares in the initial reaction.
Impact level
● Low
Affected assets
NCSKABBV2USD/USDT+1.24%
AI Insight · NCSKABBV2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
AbbVie reported Q2 2026 revenue of $16.990 billion and adjusted EPS of $3.65, both above consensus, but ABBV fell 2.51% in the completed reaction session. This analysis examines immunology growth, Humira erosion and the Apogee-related guidance reduction.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.